Nurse Practitioner, Family · Fayetteville, NC
NPI
1285982173
Since 2012
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
105 Roxie Ave
Fayetteville, NC, 28304
Phone (910) 609-1880
Groups this clinician bills Medicare through
Medicare paid, 2024
$81K
1,329 services
Medicare patients, 2024
372
Average age 72
Drug cost, 2024
$3.2M
5,512 prescriptions
Company payments, 2025
$2,965
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mary E Schultz-Villarreal was code 99214 (office e&m - established), 950 times for 354 patients. In total Mary E Schultz-Villarreal billed 1,329 services in 4 codes, and Medicare paid $81K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 950 | 354 | $74.04 | $70K |
| 95251 Test - Miscellaneous | Office | 325 | 115 | $21.15 | $6,875 |
| 99213 Office E&M - Established | Office | 32 | 21 | $56.40 | $1,805 |
| 99204 Office E&M - New | Office | 22 | 22 | $90.92 | $2,000 |
By year: 2022 $79K for 1,252 services; 2023 $72K for 1,267 services; 2024 $81K for 1,329 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mary E Schultz-Villarreal prescribed most often to Medicare patients was Levothyroxine Sodium, with 568 prescriptions and refills. In total Mary E Schultz-Villarreal wrote 5,512 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 568 | 1,410 | 151 | $17K |
| Mounjaro Tirzepatide | 551 | 617 | 99 | $639K |
| Jardiance Empagliflozin | 422 | 654 | 75 | $378K |
| Ozempic Semaglutide | 343 | 504 | 75 | $469K |
| Metformin Hcl Generic | 171 | 428 | 50 | $1,117 |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 161 | 243 | 34 | $153K |
| Synthroid Levothyroxine Sodium | 152 | 287 | 27 | $11K |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 145 | 280 | 41 | $180K |
| Tresiba Flextouch U-200 Insulin Degludec | 138 | 226 | 37 | $167K |
| Farxiga Dapagliflozin Propanediol | 126 | 251 | 38 | $133K |
| Rosuvastatin Calcium Generic | 118 | 320 | 45 | $1,213 |
| Metformin Hcl Er Metformin Hcl | 105 | 268 | 32 | $748 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 101 | 189 | 29 | $12K |
| Novolog Flexpen Insulin Aspart | 95 | 174 | 33 | $31K |
| Atorvastatin Calcium Generic | 92 | 263 | 27 | $736 |
Brand drugs: 3,552 claims; generic drugs: 1,656 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mary E Schultz-Villarreal $2,965 ($2,965 in general payments such as food, travel and fees) from 29 companies. The largest payer was Novo Nordisk Inc with $501.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.